<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233440</url>
  </required_header>
  <id_info>
    <org_study_id>CSL654_2001</org_study_id>
    <secondary_id>1508</secondary_id>
    <secondary_id>2010-018477-38</secondary_id>
    <nct_id>NCT01233440</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B</brief_title>
  <official_title>An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety of IV administration of rIX-FP.
      Safety will be evaluated by adverse events and laboratory changes over time. The secondary
      objective of the study is to evaluate the pharmacokinetics parameters, following a single
      intravenous dose of rIX-FP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is comprised of both a rIX-FP dose-escalation safety segment (25, 50 and 75 IU/kg
      of rIX-FP), and PK evaluation of rIX-FP after a single dose of 50 IU/kg, as well as PK
      evaluation after a single dose of 50 IU/kg of the previously given Factor IX (FIX) product
      (recombinant FIX [rFIX] or plasma derived FIX [pdFIX]) which is used as the reference
      product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>up to 14 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>up to 28 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of inhibitor against FIX</measure>
    <time_frame>up to 28 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of antibodies against rIX-FP</measure>
    <time_frame>up to 28 days after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC to the last sample with quantifiable drug concentration (AUC0-t)</measure>
    <time_frame>From time of dosing up to 7 days after the dose</time_frame>
    <description>Following 50 IU/kg rIX-FP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC extrapolated to infinity (AUCt-∞)</measure>
    <time_frame>From time of dosing up to 7 days after the dose</time_frame>
    <description>Following 50 IU/kg rIX-FP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>From time of dosing up to 7 days after the dose</time_frame>
    <description>Following 50 IU/kg rIX-FP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental recovery (IU/mL/IU/kg)</measure>
    <time_frame>From time of dosing up to 7 days after the dose</time_frame>
    <description>Defined as FIX activity (IU/mL) obtained 30 minutes following infusion, per dose of (IU/kg) infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>From time of dosing up to 7 days after the dose</time_frame>
    <description>Following 50 IU/kg rIX-FP infusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 IU/kg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 IU/kg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 IU/kg dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Coagulation Factor IX Albumin Fusion Protein</intervention_name>
    <description>Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma derived FIX [pdFIX]</intervention_name>
    <description>Single dose of 50 IU/kg of reference product, given as intravenous infusion</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, 12 - 65 years, with body weight ≥ 30 kg and ≤ 120 kg

          -  Documented severe Hemophilia B (FIX activity of ≤ 2%) or tested by the central
             laboratory at screening

          -  Subjects who have received FIX products for &gt; 150 exposure days (EDs) (estimated)

          -  No confirmed prior history of FIX inhibitor (history of positive FIX inhibitor defined
             as two consecutive positive tests - a confirmatory test on a second, separately drawn
             sample shortly after the previous positive test) and confirmed no detectable FIX
             inhibitors (negative FIX inhibitor defined as &lt; 0.6 Bethesda Units [BU] by the central
             laboratory at screening

          -  Subjects can be treated on-demand or under prophylactic therapy

          -  Signed Informed Consent/Assent

        Exclusion Criteria:

          -  Known hypersensitivity (allergic reaction or anaphylaxis) to any FIX product or
             hamster protein

          -  Any known congenital or acquired coagulation disorder other than congenital FIX
             deficiency

          -  Platelet count &lt; 100,000/µL

          -  Immunocompromised (CD4 count &lt; 200/mm3), (HIV positive subjects may participate in the
             study and protease inhibitors and antiviral therapy are permitted, at the discretion
             of the Investigator)

          -  Currently receiving IV immunomodulating agents such as immunoglobulin or chronic
             systemic corticosteroid treatment

          -  Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT)
             concentration &gt; 5 times (x) the upper limit of normal (ULN)

          -  Serum creatinine &gt; 2 x ULN

          -  Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism,
             myocardial infarction and arterial embolus within 3 months prior to enrollment

          -  Use of an Investigational Medicinal Product (IMP) within 30 days prior to the first
             rIX-FP administration

          -  Experienced life-threatening bleeding episode or had major surgery or an orthopedic
             surgical procedure during the 3 months prior to study entry

          -  Subject currently on a dose and/or regimen of FIX that would preclude participation in
             the study due to possible increased risk of bleeding because of the requirement to
             withhold treatment during the PK sampling period

          -  Suspected inability (e.g., language problem or mental condition) or unwillingness to
             comply with study procedures or history of noncompliance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Jacobs, MD</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT01233440&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

